Her kan du lese mer om den forskningen som vi og våre søster-stiftelser i Sverige og Finland har vært med på å finansiere siden starten i 2008. Vi støtter både forskning innenfor diabetes typ1 og diabetes type 2.

Diabetes Wellness søker aktivt etter prosjekter som antas å ha de beste forutsetninger for å utvikle forbedrede behandlingsmåter eller å komme nærmere en endelig kur for diabetes.

Vår rådgivende komité vurderer mottatte søknader og gir sin anbefaling til styret, som fatter den endelige beslutningen.

Siden starten har Diabetes Wellness Sverige finansiert forskning for nærmere 100 millioner kroner, takket være de gavmilde menneskene som har valgt å støtte vårt arbeide.

Diabetes Wellness Norge er fortsatt relativt ung, og vi arbeider med å etablere en stabil base med støttespillere som kan hjelpe oss å finansiere forskning, både i Norge og utlandet.

Inntil videre kan du lese om noen av de prosjektene som vår svenske søsterorganisasjon har støttet.


Vil du være med og støtte forskningen?

Gjennom å støtte Diabetes Wellness Norge hjelper du oss i kampen mot diabetes. Din støtte bidrar ikke bare til å finansiere forskning på diabetes, men også til å informere allmennheten om sykdommen og dens mange farlige komplikasjoner.

Du hjelper oss ved å betale inn et valgfritt beløp til vår bankkonto 9046 12 86215. Husk at alle beløp er til nytte, og at ingen gave er for liten.

2020

Dr Olof Eriksson, Uppsala Universitet

1 303 200 SEK

GPR44 as a PET marker for measuring beta cell mass in human.

Professor Patrik Rorsman, Göteborgs Universitet

2 000 000 SEK

Pathophysiologycaemia risk in insulin-treated diabetes patients:more than the sum of the parts? Typ 1 diabetes.

Professor Anders Tengholm, Uppsala Universitet

2 000 000 SEK

Rap and Ras signalling in insulin secretion.

Dr Ingrid Wernstedt Asterholm, Göteborgs Universitet

2 000 000 SEK

Succinate-induced glucose uptake in skeletal muscle - a new therapeutic target for diabetes?

2017

Dr. Mototsugu Nagao, Lunds Universitet

200 000 SEK

CD36 as a therapeutic target to improve beta cell function in type 2 diabetes

Dr. Oskar Skog, Uppsala Universitet

200 000 SEK

Characerization of the diabetic pancreas to unravel the pathogenesis and etiology of type 1 diabetes

Dr. Andreas Edsfeldt, Lunds Universitet

200 000 SEK

Diabetes associated vascular complications caused by impaired efferocytosis, inflammatory resolution and fibrotic tissue repair

Professor Nils Wierup, Lunds University

2 000 000 SEK

Discovery and functional validation of regulatory networks in human pancreatic islets to identify targetable disease mechanisms underlying Type 2 diabetes

Dr. Emma Ahlqvist, Lund University

1 981 000 SEK

How many diseases are type 2 diabetes? Confirmation, evaluation and implementation of a new diabetes subclassification

Dr. Evelina Vågesjö, Uppsala University

200 000 SEK

Mechanisms in skin wound healing in non-diabetic and diabetic conditions and the effect of wound treatment with chemokines

Professor Lena Eliasson, Lund University

2 000 000 SEK

Novel therapeutic tools and new biomarkers in diabetes with focus on islet specifik microRNAs

Dr Bernard Hering, University of Minnesota

850 000 SEK

Refining Immunosuppression to Prevent Rejection of Porcine Islet Xenografts

Dr. Abdul Waheed Khan, Karolinska Institutet

200 000 SEK

Role of acetyltransferase GCN5 in endothelial oxidative stress in diabetes

Professor Per-Ola Carlsson, Uppsala University

2 000 000 SEK

Translational studies of insulinsecreting cells derived from induced pluripotent stem cells

Dr Bernard Hering, University of Minnesota, Diabetes Institute for Immunology and Transplantation

167 000 USD

Spring Point Project, its mission is to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes

2016

Dr Anna Nordström, Umeå universitet

1 000 000 SEK

6000 steps for better health – a randomised 12-month intervention study

Dr Anya Medina Benavente, Lunds Universitet

200 000 SEK

Autophagy in control of beta-cell mass and function in Type 2 Diabetes

Dr Luis Sarmiento, Lunds Universitet

200 000 SEK

Communication between virus-infected pancreatic beta-cells and the immune system: implication for Type 1 diabetes

Dr Jennifer Jager, Karolinska Institutet

200 000 SEK

Contribution of genes and non-coding RNAs expressed by Kupffer cells in insulin resistance

Professor Fredrik Bäckhed, Göteborgs universitet

2 000 000 SEK

Determining the microbiota in subjects with prediabetes

Dr Joan Domingo-Espin, Lunds universitet

200 000 SEK

Does Glycation of apoA-I links to higher risk of cardiovascular complications in diabetic patients?

Dr Midhat Abdulreda, Diabetes Research Institute Miami University

900 000 SEK

In collaboration with Prof. PO Berggren, Karolinska Institutet: Evaluating vision in the baboon following pancreatic islet transplantation in the eye anterior chamber

Dr Rashmi Prasad Bokkasa, Lunds universitet

200 000 SEK

Genetic and transcriptomic studies of fetal pancreas to understand fetal programming and development and identification of blood based biomarkers for pancreatic development

Professor Erik Renström, Lunds universitet

1 983 349 SEK

Growth differentiation factor 11 (GDF11) – a fons adolescentia for the pancreatic beta-cell that can delay or prevent onset of type 2 diabetes?

Dr Olof Lagerlöf, Karolinska Institutet

1 938 350 SEK

Molecular control over a neuronal circuit that mediates feeding behaviour – and important new target in the fight against diabetes

Dr Bernard Hering, University of Minnesota

850 000 SEK

Refining Immunosuppression to Prevent Rejection of Porcine Islet Xenografts

Professor Eva Degerman, Lunds Universitet

346 000 SEK

Short chain fatty acids; gut metabolites with implications for metabolic health

Professor John Pernow, Karolinska Institutet

1 000 000 SEK

The importance of endothelial and red blood cell dysfunction for vascular complications in type 2 diabetes

Professor Olle Korsgren, Uppsala universitet

1 800 000 SEK

The role of the duodenal microbiota in the etiopathology of Type 1 Diabetes

Dr Bernard Hering, University of Minnesota, Diabetes Institute for Immunology and Transplantation

167 000 USD

Spring Point Project, its mission is to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes

2015

Per-Olof Berggren, Karolinska Institutet

2 000 000 SEK

An in vivo approach to understand inositide signalling in the pancreatic beta cell

Anders Tengholm, Uppsala Universitet

1 000 000 SEK

Betydelsen av budbärarämnet cAMP för reglering av insulin- och glukagonfrisättningen

Peetra Magnusson, Uppsala Universitet

250 000 SEK

Cellular interactions of mesenchymal stromal cells in type 1 diabetes

Karin Stenkula, Lunds Univeristet

250 000 SEK

Correlation between systemic insulin resistance and bimodal adipose cell response

Margit Mahlapuu, Göteborg universitet

925 000 SEK

En ny unik medicinsk behandling av typ-2 diabetes baserat på hämmandet av proteinkinaset STK25

Charlotte Ling, Lunds universitet

1 000 000 SEK

Hur påverkar fetma och typ 2 diabetes muskelstamcellernas funktion?

Olov Andersson, Karolinska Institutet

1 000 000 SEK

Novel strategies for treating diabetes

Mia Phillipson, Uppsala Universitet

1 002 000 SEK

The role of pancreatic macrophages for development and maturation of islets of Langerhans and long-term metabolic control

Dariush Mokhtari, Akademiska Sjukhuset Uppsala

250 000 SEK

Tissue factor signaling in islets and beta-cells

Juleen Zierath och Anna Krook, Karolinska Institutet

1 000 000 SEK

Träningsintervention vid metabola sjukdomar

Helena Edlund, Umeå Universitet

2 000 000 SEK

Typ 2 diabetes: en betacellsdegenerativ sjukdom?

Francesco Paneni, Karolinska Institutet

250 000 SEK

Understanding redox signalling in diabetic cardiomyopathy: role of AP-1 transcription factor JunD

Ola Hansson, Lunds universitet

1 000 000 SEK

Vilken påverkan har ärftlighet på muskelegenskaper och metabolsjukdom? - funktionen av RAB3GAP2 och MAOA

2014

Sebastian Barg, Uppsalas universitet

2 000 000 SEK (2015-2016)

Assembly of the insulin granule secretory machinery

Gunilla Westermark, Uppsalas universitet

240 000 SEK (2015)

Can high concentrations of IAPP in plasma indicate the formation of beta-cell toxic species?

Hindrik Mulder, Malmö

950 000 SEK (2015)

Dissecting the role of mitochondrial dysfunction in pancreatic beta-cells in Type 2 Diabetes

Nils Welsh, Uppsalas universitet

300 000 SEK (2015)

Does brusatol counteract high-fat diet-induced glucose intolerance in mice?

Karl Tryggvason, Karolinska Intstitutet

1 000 000 SEK (2015)

Expansion of pancreatic islets in vitro and transplantation treatment in diabetic mice

Nils Wierup, Lunds universitet

2 000 000 SEK (2015-2016)

Gastric bypass surgery as a model for identification of new treatments for Type 2 Diabetes

Ingrid Wernstedt Asterholm, Göteborgs universitet

300 000 SEK (2015)

Mechanisms underlying 'browning' of white adipose tissue

Luca Inverardi, M.D, Diabetes Research Institute in Miami

669 400 SEK

Myeloid-derived suppressor cells for tolerance to islet transplants

Isabella Artner, Lunds universitet

2 000 000 SEK (2015-2016)

Neural control of the endocrine pancreas - from molecular pathways to human physiology in health and disease

Ulf Ahlgren, Umeå universitet

683 000 SEK (2015)

Novel approaches for monitoring of endogenous ?-cells

Olle Korsgren, Uppsalas universitet

1 000 000 SEK (2015)

Quantitate imaging as a tool to characterize the ongoing pathophysiology in children with recent onset type 1 diabetes

Juleen Zierath, Karolinska Institutet

200 000 SEK

Targeted exercise intervention in the prevention of metabolic disease

Erik Renström, Lunds universitet

2 000 000 SEK (2015-2016)

The gamma-4 subunit of voltage-gated calcium ion channels (CaV?4) is an effector of beta-cell dedifferentiation in type 2 diabetes and a potential target for disease-modifying treatment

John Pernow, Karolinska Institutet

2 000 000 SEK (2015-2016)

The role of arginase as a novel therapeutic target to improve cardiovascular function in type 2 diabetes

Per-Ola Carlsson, Uppsalas Universitet

830 000 SEK (2015-2016)

Transplantation of human islets in oxygenated macrocapsules to patients with type 1 diabetes mellitus

2013

Leif Jansson, Uppsala universitet

1 320 000 SEK (2014-2015)

A systematic exploration of proteins for future site-targeted delivery of therapeutics to the native human islets

Daniel Nyqvist, Karolinska Institutet

300 000 SEK (2014)

Characterisation of VEGF-B as a regulator of pancreatic B-cell lipid handing and function

Jorge Lira Ruas, Karolinska Institutet

1 200 000 SEK (2014-2015)

Farnesoid X receptor isoforms and their roles in liver energy metabolism

Albert Salehi, Lunds universitet

1 320 000 SEK (2014-2015)

Insulin suppresses counterregulatory glucagon secretion by an indirect effect mediated by stimulation of somatostatin secretion from delta cells

Bryndis Birnir, Uppsala University

2 000 000 SEK (2014-2015)

Interstitial GABA regulates alpha, beta and delta cells in human islets

Jan Boren, University of Gothenburg

2 000 000 SEK (2014-2015)

Mechanisms for and consequences of ectopic lipid accumulation

Margit Mahlapuu, Göteborg universitet

400 000 SEK (2014)

Molecular mechanisms and treatment strategies of T2DM

Annika Rosengren, Sahlgrenska University Hospital

431 000 SEK (2014)

Normalizing risk of death and cardiovascular diseases in type 1 diabetes

Olle Korsgren, Uppsalas universitet

660 000 SEK (2014)

Rediscovery of the etiology of T1D in humans

Rayner Rodriguez-Diaz, Rolf Luft Centre for Diabetes Research

1 013 500 SEK (2014-2015)

Study of the neuroimmune synapse in the islet of Langerhans

Dr Bernard Hering, University of Minnesota

1 200 000 SEK (2014-2015)

Funding of this grant will help Spring Point Project achieve its mission to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes

2012

Ulf Ahlgren, Umeå universitet

850 000 SEK

A novel approach for non-invasive monitoring of endogenous beta-cells

Sebastian Barg, Uppsalas universitet

1 200 000 SEK för år 2013-2014

Characterization of proteins and drugs that effect insulin granule docking

Erik Renström, Lunds universitet

1 200 000 SEK för år 2013-2014

Drug Repositioning to Prevent Activity-Dependent Calcium Signals in Pancreatic Beta-cells and Type-2 Diabetes Progression

Lena Eliasson, Lunds universitet

1 200 000 SEK för år 2013-2014

GIP and ostepontin in islet cell function- can GIPR variants influence response to treatment in type-2 diabetes?

Per-Olof Berggren, Karolinska Institutet

400 000 SEK

In vivo imaging of functional pancreatic beta-cell mass

Hindrik Mulder, Lunds universitet

300 000 SEK

Islet metabolism and circadian rhythm

Mia Phillipson, Uppsala Universitet

440 000 SEK

Local bioengineering of muscle prior to islet transplantation to improve engraftment and induce immunological shielding

Per-Ola Carlsson, Uppsalas Universitet

1 200 000 SEK för år 2013-2014

Means to preserve and restore beta-cell mass in type 1 diabetes mellitus

Susanna Cardell, Göteborgs universitet

1 200 000 SEK för år 2013-2014

Mechanistic studies of a novel mucosal tolerance-inducing molecule that type-1 diabetes

Margit Mahlapuu, Göteborg universitet

300 000 SEK

Molecular mechanisms and treatment strategies of T2DM

2011

Per-Olof Berggren

276 000 SEK

Biomarkers for functional pancreatic beta-cell mass

Per-Anders Jansson, Sahlgrenska Universitetsjukhuset

518 000 SEK

Clinical and experimental studies of insulin resistance

Erik Ingelsson, Karolinska Institutet

518 000 SEK

Genetics of Insulin sensivity: An integrated approach to discovery

Hindrik Mulder, Lunds universitet

424 000 SEK

Islet metabolism circadian rhythm melatonin receptors and clock genes

Margit Mahlapuu, Sahlgrenska universitetssjukhus

518 000 SEK

Molcular mechanism and treatment strategies of Type-2 diabetes

Luca Inverardi, M.D, Diabetes Research Institute in Miami

700 000 SEK

Myeloid-derived suppressor cells for tolerance to islet transplants

Gun Frisk, Uppsalas universitet

341 000 SEK

Ongoing pathogenic processes in the pancreas at onset or prior to onset of Type 1 Diabetes in humans

Anna Krook, Karolinska Institutet

518 000 SEK

Regulation of skeletal muscle insulin resistance

Per-Ola Carlsson, Uppsalas universitet

621 000 SEK

Stem cell therapies to regenerate the endocrine pancreas in type 1 diabetes mellitus

Mikael Rydén, Karolinska Institutet

518 000 SEK

Transcription factors regulating insulin sensivity in human adipose tissue

Claes Wadelius, Uppsalas universitet

518 000 SEK

Translating genetic associations for Type-2 diabetes to biological processes using chromatin maps

2010

Professor Gwyn Gould, University of Glasgow

£20,000.00

Analysis of tethering factors in the regulation of Glut4 spatial dynamics

Dr Katarina Kos, Peninsula Medical School

£19,260.00

Are human SPARC isoforms suitable peripheral makers of insulin resistance and diabetes-related complications?

Cesare Patrone, Karolinska Institutet

525 000 SEK

GLP-1R activation for the treatment of stroke in diabetes

Daniel Brandhorst, Rudbeck Laboratory

945 000 SEK

Hybrid preservation fluids and modular enzyme systems: significant means to optimizehuman islet transplantation

Dr Catherine Arden, Newcastle University

£13,665.00

Investigation of the association between glucokinase and the pro-apoptotic protein BAD in pancreatic beta-cells

Dr Gaya Thanabalasingham, Oxford Centre for Diabetes

£19,211.40

Investigation of the incretin pathway in Maturity onset diabetes of the young (MODY) secondary to heterozygous hepatocyte nuclear factor 1 alpha (HNF1A) gene mutations

Per-Ola Carlsson, Uppsala Biomedicinska centrum, BMC

525 000 SEK

Mesenchymal Stem Cells for Treatment of Newly Onset Type 1 Diabetes

Dr Neil Reeves, Manchester Metropolitan University

£19,423.00

Peripheral neuropathy and muscle weakness: how do they influence the safety of daily gait tasks for people with diabetes?

Henrik Ortsäter, Karolinska Institutet

525 000 SEK

Protein phosphate 5 can protect pancreatic beta-cells against the diabetogenic propeties of glucocorticoids and a high-fat diet

Dr Lazaros Foukas, University College London

£19,662.00

Role of adipose tissue in age-dependent beneficial effects of PI 3-kinase pathway inactivation on glucose and lipid homeostasis

Dr Jeremy Turner, University of East Anglia

£9628.00

The regulation of metalloproteinases and tissue inhibitors of metalloproteinases in adipose inflammation and type2diabetes

The Spring Point Project in Minneapolis, University of Minnesota

$200 000 USD

Funding of this grant request will help Spring Point Project achieve its mission to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes

2009

Åke Sjöholm, Karolinska Institutet

400 000 SEK

Exendin-4 protection of normal and diabetic human coronary artery endothelial cells in diabetic macroangiopathy

David Erlinge, Lunds universitetssjukhus

200 000 SEK

Extracellular nucleotide receptors as targets for the treatment of diabetes

Mrs Melanie Cope, DRWF Islet Isolation Facility Oxford UK

£27,696.00 GBP

Funding of Islet Transplant Administrator within the DRWF Islet Isolation Facility

Olle Korsgren, Rudbecklaboratoriet

500 000 SEK

Hybrid preservation fluids and modular enzyme systems: significant means to optimize human islet transplantation

2008

Olle Korsgren, Uppsalas universitet

200 000 SEK

Development of a protocol using LMW-DS and Compstatin to inhibit the IBMIR in xenogeneic islet transplantation

Åke Sjöholm, Karolinska Institutet

200 000 SEK

Exendin-4 protection of normal and diabetic human coronary artery endothelial cells in diabetic macroangiopathy

David Erlinge, Lunds universitetssjukhus

200 000 SEK

Extracellular nucleotide receptors as targets for the treatment of diabetes